TY - JOUR T1 - Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00166-2021 SP - 2100166 AU - Andrew P. Hearn AU - Oliver D. Hug AU - Ziana A. Somani AU - Joanne Kavanagh AU - Grainne d'Ancona AU - Cris Roxas AU - Linda Green AU - Louise Thomson AU - Mariana Fernandes AU - Brian D. Kent AU - Jaideep Dhariwal AU - Alexanda M. Nanzer AU - David J. Jackson Y1 - 2021/01/01 UR - http://erj.ersjournals.com/content/early/2021/02/11/13993003.00166-2021.abstract N2 - Mepolizumab and benralizumab are monoclonal antibodies (mAbs) approved for the treatment of severe eosinophilic asthma (SEA), targeting IL-5 and IL-5R respectively [1]. In appropriately selected patients, their use leads to significant reductions in asthma exacerbations and maintenance oral corticosteroid (mOCS) dose [2, 3].FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Hearn has nothing to disclose.Conflict of interest: Mr. Hug has nothing to disclose.Conflict of interest: Ms. Somani has nothing to disclose.Conflict of interest: Dr. Kavanagh reports other from Teva, outside the submitted work.Conflict of interest: Dr. d'Ancona reports personal fees and other from Teva, personal fees from GSK, personal fees from Astra Zeneca, personal fees from Chiesi, personal fees from Napp, outside the submitted work.Conflict of interest: Ms. Roxas has nothing to disclose.Conflict of interest: Ms. Green has nothing to disclose.Conflict of interest: Ms. Thomson has nothing to disclose.Conflict of interest: Ms. Fernandes has nothing to disclose.Conflict of interest: Dr. Kent reports personal fees and other from Teva, personal fees from GSK, personal fees from Astra Zeneca, personal fees from Chiesi, from Napp, outside the submitted work.Conflict of interest: Dr. Dhariwal reports other from Sanofi, outside the submitted work.Conflict of interest: Dr. Nanzer reports other from Napp, personal fees from Astrazeneca, outside the submitted work.Conflict of interest: Dr. Jackson reports personal fees and other from Teva, personal fees from GSK, personal fees from Astra Zeneca, personal fees from Chiesi, personal fees from Napp, outside the submitted work. ER -